Last reviewed · How we verify
Ovulation triggering with GnRH-a
At a glance
| Generic name | Ovulation triggering with GnRH-a |
|---|---|
| Sponsor | Fundación Santiago Dexeus Font |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Interest of Sperm Insemination at 42 Hours Post hCG Compared to 36h in Intrauterine Insemination (NA)
- Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles (PHASE3)
- Fertility Preservation in Breast Cancer Patients (PHASE4)
- Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE) (PHASE4)
- Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer (PHASE2)
- Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol (NA)
- Luteal Phase Ovarian Stimulation With Follitropin Delta and Dydrogesterone (NA)
- Dual Ovarian Stimulation (Duostim) and Shanghai Protocols in Poor Ovarian Responders (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |